Drug Search Results
More Filters [+]

GB-0998

Alternative Names: gb-0998, gb0998, gb 0998
Latest Update: 2022-01-28
Latest Update Note: Clinical Trial Update

Product Description

intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization for End Stage Renal Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02032095)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Japan Blood Products Organization
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GB-0998

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Myasthenia Gravis|Abortion, Spontaneous|Muscle Weakness|Abortion, Habitual|Guillain-Barre Syndrome|Dermatomyositis|Polymyositis|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B211-11

P3

Completed

Abortion, Spontaneous|Abortion, Habitual

2020-05-01

50%

B211-13

P3

Completed

Guillain-Barre Syndrome

2015-09-01

B211-10

P3

Completed

Kidney Failure, Chronic

2015-09-01

0998-B1

P3

Completed

Muscle Weakness|Myasthenia Gravis

2010-05-01

Recent News Events

Date

Type

Title